October 9, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary interventio"...



NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels and the radial muscle of the iris.

The ophthalmologic usefulness of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride is due to its rapid effect and moderately prolonged action, as well as to the fact that it produces no compensatory vasodilatation.

The action of different concentrations of ophthalmic solutions of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride is shown in the following table:

Strength of solution (%) Mydriasis Paralysis of accomodation
Maximal (minutes) Recovery time (hours)
2.5 15-60 3 trace
10 10-60 6 slight

Although rare, systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic effects, such as rise in blood pressure which may be accompanied by a reflex atropine-sensitive bradycardia.

Last reviewed on RxList: 5/6/2008
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Heart Health

Get the latest treatment options.

Atrial Fibrillation Quiz